Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Merck Diversifies Beyond Keytruda, It Will Lean On Its Oncology Leadership Position

Cardiology, Infectious Diseases Also Remain Core Areas

Executive Summary

Merck Research Laboratories president Dean Li said there is no ideal product mix for the company, but noted cancer drugs will remain a priority given the groundwork Keytruda laid for Merck in oncology.

You may also be interested in...



Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: Merck & Co. tells Scrip oncology will remain a key priority; J&J is responsibly cautious on growth; Takeda pays big for HutchMed drug; industry looks at likely US IRA impact; and lecanemab misses out on EU fast-track treatment.

J.P. Morgan Day One: Biopharma Braces For Headwinds Ahead

Daily notebook from the J.P. Morgan Healthcare Conference: Turbulent weather matches sentiment about the year ahead, with investors looking for reassurance on the IRA, deal-making and growth strategy from big pharma. Updates from J&J, Biogen, BMS, Merck and more.

IRA Already Impacting Merck & Co. BD Decisions, CEO Davis Says

Merck & Co. CEO Rob Davis said the company is already factoring policy changes from the Inflation Reduction Act into its business development decisions.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel